Abstract
Background: Oncotype DX™ (ODX) individualises patient adjuvant therapy whilst estimating prognosis. ODX relies on genetic signatures; the histopathological phenotype of which are tested routinely. We aimed to correlate ODX scores with clinicopathological and immunohistochemical data, and thus determine whether these parameters are complementary with ODX, without impacting oncological outcome.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
